Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
STRO
SELLSutro Biopharma, Inc. · Healthcare · United States · $379M · Avg Vol: $10M/d
21
StockRankGet insider-trade alerts
Q
18
V
27
M
61
P/E (TTM)
—
ROE
—
D/E
—
Dividend %
—
Loading 1Y...
PRICE (1Y)-16.6%
SMA 50SMA 200
Close
$24.01
RSI (14)
17.3
52W High
$43.85
From 52W High
0.5%
SCORE BREAKDOWN
Quality
18
ROIC
-113.3%5.2
ROE
—N/A
GP/Assets
-29.8%3.4
Op. Margin
-203.9%14.0
FCF/Assets
-87.5%2.2
Piotroski
239.0
Int. Cover
-2.7x31.9
D/E Ratio
—N/A
Current Ratio
3.12x55.3
Value
27
P/E (TTM)
—N/A
EV/EBITDA
-2.4x25.0
P/FCF
—N/A
P/B
-5.7x25.0
P/S
3.8x49.4
Div Yield
—N/A
Momentum
61
52W High %
55%32.2
RS 6M
52%93.9
SMA 50/200
1.40x96.8
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+58%59.0
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$379M
P/E (Forward)
-3.3x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of STRO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| STRO | Sutro Biopharma, Inc.(you) | $379M | 21 | SELL |
| ENTA | Enanta Pharmaceuticals, Inc. | $372M | 23 | SELL |
| BNTC | Benitec Biopharma Inc. | $394M | 24 | SELL |
| LRMR | Larimar Therapeutics, Inc. | $416M | 23 | SELL |
| IMRX | Immuneering Corporation | $279M | 21 | SELL |
| RCKT | Rocket Pharmaceuticals, Inc. | $348M | 16 | STRONG SELL |
| ZURA | Zura Bio Limited | $496M | 22 | SELL |
| IPSC | Century Therapeutics, Inc. | $381M | 28 | SELL |
| RZLT | Rezolute, Inc. | $480M | 23 | SELL |
| PRLD | Prelude Therapeutics Incorporated | $305M | 24 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%